Zhejiang Cancer Hospital: Small Cell Lung Carcinoma trials

The registry lists 11 Small Cell Lung Carcinoma studies with Zhejiang Cancer Hospital as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 2 10Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung CancerRecruitingNCT06562920Phase 2
• A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCRecruitingNCT05896059Phase 2
• PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC PatientsRecruitingNCT05651802Not applicable
• A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLCRecruitingNCT04543890Phase 2
• A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLCCompletedNCT06478043Phase 2
• A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCActive, not recruitingNCT05228496Phase 2
• A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLCStatus unknownNCT04967625Phase 2
• Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLCStatus unknownNCT04189094Phase 2
• Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)Status unknownNCT02906384Phase 2
• A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung CancerStatus unknownNCT01731548Phase 2/3
• Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung CancerStatus unknownNCT01635400Phase 2